Shire
VC Fund
Dublin, Ireland
Shire is a VC fund in Dublin focused on Biotechnology and Health Care. Shire is the leading global biotechnology company focused on serving people with rare diseases. They have a global sales and marketing infrastructure with a broad portfolio of products and direct marketing capability in the US, Canada, UK, Republic of Ireland, France, Germany, Italy and Spain.At Shire, the company ground everything they do intheir purpose of enabling people with life altering conditions to lead better lives. The company's patient and customer focused culture encourages employees to embrace innovation and challenge the status quo through respectful and inclusive engagement with colleagues. Honesty and transparency are inherent in all that we do as we work with a high sense of urgency to become a leading global biotech delivering innovative therapies to patients with rare diseases and other specialty conditions. We foster an environment where leaders are positive, accountable, results driven and great people managers. Our employees own their development in partnership with their manager, understand and leverage their strengths, bring their whole selves to work, and like the leaders they are expected to eventually become, share the essential traits of positive, accountable and results driven. Our non-hierarchical structure and clear reporting lines enable quick decision making, nimble execution and the opportunity for employees to enjoy the work and grow to their fullest potential. The company is committed to recruit, develop and retain top talent who take a responsible and ethical approach to all that we do and who want to make a difference in the lives of patients across the globe.
- Total investments:
- 12
- Last investment:
- Lead investor:
- 17%
Last updated:
For AI agents: llms.txt
Industries Shire invests in
Stages Shire invests in
Countries Shire invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
| See all 9 contacts → | |||
Investment Focus
Industry
- Biotechnology 8 (67%)
- Health Care 5 (42%)
- Therapeutics 5 (42%)
- Biopharma 3 (25%)
- Life Science 2 (17%)
Stage
- Series B 3 (25%)
- Series C 3 (25%)
- Series A 2 (17%)
- Series D 2 (17%)
- Funding Round 1 (8%)
Country
- United States 6 (50%)
- France 1 (8%)
- Belgium 1 (8%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Anne Minto
Non-Executive Director
|
Non-Executive Director | Total investments: 0 | Find email | |
Anthony Trupiano
Director Combination Product Device Development
|
Director Combination Product Device Development | Total investments: 0 | Find email | |
|
Bernhard Schimmele
Head Global Stability
|
Head Global Stability | Total investments: 0 | Find email | |
|
Christa Tauer
VP Process Development Biologics
|
VP Process Development Biologics | Total investments: 0 | Find email | |
Dhairya Mehta
Associate Director of Device and Combination Products
|
Associate Director of Device and Combination Products | Total investments: 0 | Find email | |
| See all 9 team members → | ||||
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Rani is a clinical stage biotherapeutics company advancing technologies to enable the development of orally administered biologics, which we believe will have the potential to transform medicine and improve patient outcomes. We have developed the RaniPill capsule, which is our novel, proprietary and patented platform technology, intended to replacesubcutaneous or IV injection of biologics with oral dosing. The RaniPill capsule is an orally ingestible pill approximately the size of a “000” capsule (or similar to the size of a standard fish oil or calcium pill) that is designed to automatically administer a precise therapeutic dose of medication upon deployment in the small intestine. To date, we have successfully conducted several preclinical and clinical studies to evaluate safety, tolerability and bioavailability using the RaniPill capsule. Our development efforts have enabled us to construct an extensive intellectual property portfolio that we believe provides us a competitive advantage. | $53M / Feb 07, 2018 | ||
| Promethera® Biosciences is a biopharmaceutical company, spin-off of the Université Catholique de Louvain, that develops innovative treatments based on allogeneic adult stem cell technology.Promethera® Biosciences' mission is to discover, develop and commercialize cell therapy products to treat liver diseases in an innovative way usingallogenic progenitor cells from healthy human livers.Promethera® Biosciences develops two products based on a newly discovered and patented progenitor cell type: the human Adult Liver-Derived Mesenchymal Progenitor Cell (hALDMSC): | $27.8M / Series C / Nov 25, 2014 | ||
| Naurex Inc. is a clinical-stage company developing novel therapies for depression and other CNS disorders based on a new mechanism of action for modulating the N-methyl-D-aspartic acid receptor (NMDAR). Using these discoveries, Naurex researchers have generated novel chemical drug classes known as glycine-site functional partial agonists (GFPAs),which modulate the receptor in a different way than existing NMDAR agents. The company's drug development programs based on its GFPA NMDAR modulators include the first-generation molecule, GLYX-13, the second-generation NRX-1050 small molecule series and additional compounds from Naurex's platform of novel NMDAR modulators. | $25M / Series C / May 06, 2014 | ||
| NeuroPhage Pharmaceuticals, Inc. is a biotechnology company, develops disease-modifying therapies for the treatment of neurodegenerative diseases. The company develops a protein disaggregation platform for the treatment of Alzheimer’s, Parkinson’s, Huntington’s, amyotrophic lateral and multiple sclerosis, and other neurodegenerative diseases. Itoffers NPT001, a drug candidate for Alzheimer’s disease to disaggregate existing plaque in preclinical animal models. The company was founded in 2006 and is headquartered in Cambridge, Massachusetts. | $17M / Series D / Mar 25, 2014 | ||
| NeuroPhage Pharmaceuticals, Inc. is a biotechnology company, develops disease-modifying therapies for the treatment of neurodegenerative diseases. The company develops a protein disaggregation platform for the treatment of Alzheimer’s, Parkinson’s, Huntington’s, amyotrophic lateral and multiple sclerosis, and other neurodegenerative diseases. Itoffers NPT001, a drug candidate for Alzheimer’s disease to disaggregate existing plaque in preclinical animal models. The company was founded in 2006 and is headquartered in Cambridge, Massachusetts. | $6.4M / Series C / May 06, 2013 | ||
| ArmaGen is a developer of therapies designed to address neurological complications. The company's pipeline of innovative therapies penetrate the blood-brain barrier to treat neurological complications of many diseases, including lysosomal storage disorders (LSDs), Alzheimer's and Parkinson's, enabling patients suffering fromneurodegenerative disorders to get improved treatment. | $17M / Series A / Nov 29, 2012 | ||
| Promedior is a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of inflammatory and fibrotic diseasesPromedior has developed a novel drug discovery platform to regulate the monocyte-derived cell populations that play key roles in fibrotic, inflammatory and autoimmune diseases. By specifically targetingthese cells at the site of injury, Promedior is able to treat the source of aberrant immune system responses, promote tissue healing and resolution, and greatly reduce the risk of systemic side effects inherent in current therapeutic approaches. Promedior is developing drugs to address the most severe and difficult-to-treat fibrotic and inflammatory conditions of the eye, lung and kidney such as glaucoma, age-related macular degeneration, diabetic retinopathy and dry eye disease; pulmonary fibrosis, scleroderma and COPD; and acute and chronic nephropathy. | $3M / Series D / Oct 15, 2012 | ||
| Promethera® Biosciences is a biopharmaceutical company, spin-off of the Université Catholique de Louvain, that develops innovative treatments based on allogeneic adult stem cell technology.Promethera® Biosciences' mission is to discover, develop and commercialize cell therapy products to treat liver diseases in an innovative way usingallogenic progenitor cells from healthy human livers.Promethera® Biosciences develops two products based on a newly discovered and patented progenitor cell type: the human Adult Liver-Derived Mesenchymal Progenitor Cell (hALDMSC): | $25.9M / Series B / Mar 28, 2012 | ||
| Enterome is an integrated company leveraging its unique knowledge of the key functional and molecular interactions between the gut microbiome and the human body to develop targeted therapeutics.Enterome is focused on the identification of the bioactive molecules that are differentially expressed, secreted and regulated by the gut microbiome, whichplay a central role in the regulation of key aspects of human physiology and the immune system. | $8.2M / Series A / Mar 23, 2012 | ||
| NeuroPhage Pharmaceuticals, Inc. is a biotechnology company, develops disease-modifying therapies for the treatment of neurodegenerative diseases. The company develops a protein disaggregation platform for the treatment of Alzheimer’s, Parkinson’s, Huntington’s, amyotrophic lateral and multiple sclerosis, and other neurodegenerative diseases. Itoffers NPT001, a drug candidate for Alzheimer’s disease to disaggregate existing plaque in preclinical animal models. The company was founded in 2006 and is headquartered in Cambridge, Massachusetts. | $9M / Series B / Mar 08, 2012 | ||
| See all 12 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Shire invest in?
Shire invests primarily in Biotechnology, Health Care and Therapeutics startups, most often at Series B and Series C stage. Most of the 12 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Shire?
Public channels for Shire include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Shire?
The team at Shire includes Anne Minto (Non-Executive Director), Anthony Trupiano (Director Combination Product Device Development) and Bernhard Schimmele (Head Global Stability), among 9 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
